Citius pharmaceuticals reaches 92 event milestone in mino-lok® phase 3 trial

Cranford, n.j. , aug. 10, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has reached an important milestone in its clinical trial for mino-lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.
CTXR Ratings Summary
CTXR Quant Ranking